Related Experiment Video
Updated: Apr 24, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
The role of lectin-like oxidised low-density lipoprotein receptor-1 in vascular pathology
Daniel James Shaw1, Rachel Seese1, Sreenivasan Ponnambalam1
1Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK.
Insights
Targeting the lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) offers a promising strategy for managing vascular disease. LOX-1 plays a key role in atherosclerosis, with potential applications in diagnosis and treatment.
Area of Science:
- Vascular biology and pathology
- Cardiovascular research
Background:
- Atherothrombotic disease is a leading cause of mortality.
- The lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) is a critical scavenger receptor in vascular pathogenesis.
Purpose of the Study:
- To review the role of LOX-1 in the diagnosis and treatment of atherosclerosis.
- To explore LOX-1 as a therapeutic target and diagnostic biomarker for vascular disease.
Main Methods:
- Review of current literature on LOX-1.
- Analysis of therapeutic strategies targeting LOX-1.
- Evaluation of LOX-1's diagnostic potential.
Main Results:
- LOX-1 mediates pro-atherogenic effects that can be inhibited by specific antibodies and compounds.
- Downregulation of LOX-1 expression is achievable through antisense oligonucleotides and polyamides.
- LOX-1 can be used for plaque imaging and targeted drug delivery.
- Elevated plasma levels of soluble LOX-1 may serve as a diagnostic biomarker for atherosclerosis.
Conclusions:
- Targeting LOX-1 is a credible strategy for vascular disease management.
- LOX-1 holds significant potential for both diagnostic and therapeutic applications in atherosclerosis.
- Further research into LOX-1 modulation and utilization is warranted.
Abstract:
The lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) is a vascular scavenger receptor that plays a central role in the pathogenesis of atherothrombotic disease, which remains the main cause of mortality in the Western population. Recent evidence indicates that targeting LOX-1 represents a credible strategy for the management vascular disease and the current review explores the role of this molecule in the diagnosis and treatment of atherosclerosis. LOX-1-mediated pro-atherogenic effects can be inhibited by anti-LOX-1 monoclonal antibodies and procyanidins, whereas downregulation of LOX-1 expression has been achieved by antisense oligonucleotides and a specific pyrrole-imidazole polyamide. Furthermore, LOX-1 can be utilised for plaque imaging using monoclonal antibodies and even the selective delivery of anti-atherosclerotic agents employing immunoliposome techniques. Also, plasma levels of the circulating soluble form of LOX-1 levels are elevated in atherosclerosis and therefore may constitute an additional diagnostic biomarker of vascular pathology.
Related Concept Videos
01:30Atherosclerosis I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:38Receptor-mediated Endocytosis
01:31Lipid-derived Compounds in the Human Body
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
01:38Inflammation
01:30Peripheral Artery Disease I: Introduction